468 related articles for article (PubMed ID: 27325339)
1. Mapping the COPD Assessment Test onto EQ-5D.
Hoyle CK; Tabberer M; Brooks J
Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
[TBL] [Abstract][Full Text] [Related]
2. Mapping analysis to estimate EQ-5D utility values using the COPD assessment test in Korea.
Lim J; Choi SE; Bae E; Kang D; Lim EA; Shin GS
Health Qual Life Outcomes; 2019 Jun; 17(1):97. PubMed ID: 31170982
[TBL] [Abstract][Full Text] [Related]
3. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
Moore A; Young CA; Hughes DA
Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
[TBL] [Abstract][Full Text] [Related]
4. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
[TBL] [Abstract][Full Text] [Related]
5. Predicting EQ-5D values using the SGRQ.
Starkie HJ; Briggs AH; Chambers MG; Jones P
Value Health; 2011; 14(2):354-60. PubMed ID: 21402304
[TBL] [Abstract][Full Text] [Related]
6. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
7. Mapping algorithms for predicting EuroQol-5D-3L utilities from the assessment test of chronic obstructive pulmonary disease.
Yu CH; Chang SM; Hsu CH; Tsai SH; Liao XM; Chen CW; Lin CH; Wang JD; Hsiue TR; Chen CZ
Sci Rep; 2022 Dec; 12(1):20930. PubMed ID: 36463253
[TBL] [Abstract][Full Text] [Related]
8. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
Pullenayegum EM; Chan KK; Xie F
Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the Relationship between Capability and Health in Older People: Can't Map, Won't Map.
Franklin M; Payne K; Elliott RA
Med Decis Making; 2018 Jan; 38(1):79-94. PubMed ID: 29056069
[TBL] [Abstract][Full Text] [Related]
10. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
Kay S; Ferreira A
Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
[TBL] [Abstract][Full Text] [Related]
11. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
12. Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People's Quality of Life Brief Questionnaire (OPQoL-Brief) Scores.
Kaambwa B; Ratcliffe J
Patient; 2018 Feb; 11(1):39-54. PubMed ID: 28623629
[TBL] [Abstract][Full Text] [Related]
13. Estimating EQ-5D utilities based on the Short-Form Long Term Conditions Questionnaire (LTCQ-8).
Tsiachristas A; Potter CM; Rocks S; Peters M; Cundell M; McShane R; Batchelder L; Fox D; Forder JE; Jones K; Waite F; Freeman D; Fitzpatrick R
Health Qual Life Outcomes; 2020 Aug; 18(1):279. PubMed ID: 32795317
[TBL] [Abstract][Full Text] [Related]
14. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
15. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
Doble B; Lorgelly P
Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
[TBL] [Abstract][Full Text] [Related]
16. Assessing the external validity of algorithms to estimate EQ-5D-3L from the WOMAC.
Kiadaliri AA; Englund M
Health Qual Life Outcomes; 2016 Oct; 14(1):141. PubMed ID: 27716347
[TBL] [Abstract][Full Text] [Related]
17. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
19. Mapping the Beck Depression Inventory to the EQ-5D-3L in Patients with Depressive Disorders.
Grochtdreis T; Brettschneider C; Hajek A; Schierz K; Hoyer J; Koenig HH
J Ment Health Policy Econ; 2016 Jun; 19(2):79-89. PubMed ID: 27453455
[TBL] [Abstract][Full Text] [Related]
20. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
[No Abstract] [Full Text] [Related]
[Next] [New Search]
